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BACKGROUND: This study was designed to evaluate proton magnetic resonance spectroscopy (
1H-MRS) for monitoring the WHO
grade II glioma (low-grade glioma (LGG)) treated with temozolomide (TMZ).
METHODS: This prospective study included adult patients with progressive LGG that was confirmed by magnetic resonance imaging
(MRI). Temozolomide was administered at every 28 days. Response to TMZ was evaluated by monthly MRI examinations that
included MRI with volumetric calculations and
1H-MRS for assessing Cho/Cr and Cho/NAA ratios. Univariate, multivariate and
receiver-operating characteristic statistical analyses were performed on the results.
RESULTS: A total of 21 LGGs from 31 patients were included in the study, and followed for at least n¼14 months during treatment.
A total of 18 (86%) patients experienced a decrease in tumour volume with a greater decrease of metabolic ratios. Subsequently, five
(28%) of these tumours resumed growth despite the continuation of TMZ administration with an earlier increase of metabolic ratios
of 2 months. Three (14%) patients did not show any volume or metabolic change. The evolutions of the metabolic ratios, mean
(Cho/Cr)n and mean(Cho/NAA)n, were significantly correlated over time (Spearman r¼þ0.95) and followed a logarithmic regression
(P40.001). The evolutions over time of metabolic ratios, mean(Cho/Cr)n and mean(Cho/NAA)n, were significantly correlated with the
evolution of the mean relative decrease of tumour volume, mean(DVn/Vo), according to a linear regression (Po0.001) in the
‘response/no relapse’ patient group, and with the evolution of the mean tumour volume (meanVn), according to an exponential
regression (Po0.001) in the ‘response/relapse’ patient group. The mean relative decrease of metabolic ratio, mean(D(Cho/Cr)n/(Cho/
Cr)o), at n¼3 months was predictive of tumour response over the 14 months of follow-up. The mean relative change between
metabolic ratios, mean((Cho/NAA)n (Cho/Cr)n)/(Cho/NAA)n,a tn¼4 months was predictive of tumour relapse with a significant cutoff
of 0.046, a sensitivity of 60% and a specificity of 100% (P¼0.004).
CONCLUSIONS: The
1H-MRS profile changes more widely and rapidly than tumour volume during the response and relapse phases, and
represents an early predictive factor of outcome over 14 months of follow-up. Thus,
1H-MRS may be a promising, non-invasive tool
for predicting and monitoring the clinical response to TMZ.
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The WHO grade II gliomas (low-grade glioma (LGG)) accounts for
5–18% of all intracranial gliomas (Kleihues and Sobin, 2000).
Although the optimal treatment for LGGs is currently the subject
of debate, recent data suggest that temozolomide (TMZ; Brada
et al, 2003; Hoang-Xuan et al, 2004) influences the evolution of
LGGs (Mason et al, 1996; Chinot, 2001; Fortin et al, 2001). In
patients who are suspected to have brain tumours, magnetic
resonance imaging (MRI) is considered the gold standard for
preoperative diagnosis. In addition, MRI is the optimal tool for
gathering information for clinical decision making and monitoring
(Dowling et al, 2001). Low-grade gliomas grow slowly and often
appear as non-enhancing lesions, which makes it more difficult to
assess their growth (Macdonald, 1994; Ricci and Dungan, 2001;
Rollin et al, 2006). A volumetric evaluation may provide predictive
arguments for patient outcome, as demonstrated by some authors
(Swanson et al, 2003; Ricard et al, 2007). They performed a large
study of the dynamic course of LGGs under TMZ treatment using
mean tumour diameter (MTD) growth with a linear mixed model
(Swanson et al, 2003; Ricard et al, 2007) that was extrapolated from
serial T2-weighted images. Nevertheless, as the authors stated in
their work, the MTD remains a morphologic parameter that
requires from months to a year to provide reliable measure
assessment. Some studies (Hoang-Xuan et al, 2004; Ricard et al,
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s2007) have suggested that chemotherapy may affect tumour
burden without causing overt morphological modifications that
can be visualised by MRI, possibly by affecting the sole infiltrative
part of the glioma. The apparent response to TMZ, however, may
appear to be delayed for several months if MRI-measured tumour
volume is used as the principal parameter. Consequently, the
biological behaviour of the glioma (e.g., whether it is stable or
progressive) appears to be affected by the TMZ treatment (even at
short delays).
Metabolic data obtained from proton magnetic resonance
spectroscopy (
1H-MRS) has proved valuable in therapy evaluation
(Gill et al, 1990) and monitoring (Murphy et al, 2004). The aim of this
prospective study was to evaluate the serial metabolic changes detected
by
1H-MRS in LGGs treated with TMZ and to compare the results with
the tumour volumes calculated by MRI. To our knowledge, this study
is the first study to suggest that
1H-MRS can provide information for
predicting the outcome for patients with LGG treated with TMZ at an
earlier stage than conventional MRI volumetry.
MATERIALS AND METHODS
Patient selection
This study was a single-centre prospective study, and we used the
following criteria.
Inclusion criteria
1. Patients with histologically confirmed LGG;
2. No oncological or steroid treatment before MRI examination;
3. No contraindication to MRI investigation;
4. Imminent initiation of first-line TMZ chemotherapy.
The decision was based on usual clinical (significant increase of
seizures frequency, appearance of focal deficit) and/or radiological
(volumetric, appearance contrast enhancement) criteria of tumour
progression (Chinot, 2001; Hoang-Xuan et al, 2004; Ricard et al, 2007).
Exclusion criteria
1. Patients with radiological evidence of transformation into high-
grade tumours, including marked contrast enhancement,
oedema or necrotic areas.
2. Patients with histological evidence of transformation into high-
grade tumours, including necrosis, mitotic figures, nuclear
atypia and endothelial proliferation.
Temozolomide treatment All patients received TMZ at a dose of
200mgm
 2 per day for 5 consecutive days of a 28-day cycle. The
dose and frequency were adjusted according to standard toxicity
criteria. The intention was to give patients at least 12 cycles (up to 24)
of TMZ, and treatment was continued until we observed disease
progression or unacceptable toxicity. We only analysed the data
collected during the first 14 months, because all patient data were
available at this time.
Magnetic resonance imaging
All patients underwent an MRI examination using a whole-body
MRI (Signa 1.5T, General Electric Healthcare, Milwaukee, WI,
USA) at 2 weeks before beginning the treatment and again after
each chemotherapy cycle. The imaging evaluation included an
anatomic MRI protocol, which used the following parameters: for
T2-weighted coronal images, TR/TE 4500/100, matrix of 320 224
slice 3-mm slice thickness and 0-mm gap; for T2-FLAIR axial
images, TI/TR/TE 2200/8800/140, matrix of 228 224, 3-mm slice
thickness and 0-mm gap (bicallosal plane); for T1-weighted axial
images, TR/TE 400/9, matrix of 512 224, 4-mm slice thickness
and 0.4-mm gap. T1-weighted acquisition was repeated in the
axial and coronal planes after intravenous administration of
gadolinium. All sequences were acquired with identical positioning
at each examination.
Tumour volumetry was evaluated by measuring the region of
high-signal intensity on T2-FLAIR images with the same grey-level
windowing using BrainVisa-Anatomist software (BrainVisa-
Anatomist, CEA NeuroSpin, Saint Aubin, France; Cointepas et al,
2001), which allows for voxel-by-voxel segmentation processing
(Menuel et al, 2005).
In this study, patients who demonstrated a continuous (from
one examination to the next) decrease in tumour volume were
considered responders in a ‘response’ phase. Patients who
demonstrated (at any time during chemotherapy) a continuous
increase in tumour volume were considered to be in a ‘relapse’
phase. Patients who showed no change in tumour volume were
considered to be non-responders in a ‘no response’ phase.
The
1H-MRS data were obtained by point-resolved single-voxel
spectroscopy (TR¼1500ms/TE¼35/144ms, 96 scans). In the
initial examination, we used the same methodology as previously
published (Guillevin et al, 2008). To sample the entire tumour, we
used several voxels with a standardised volume of 6cm
3. Finally,
only the voxel within the maximal value of Cho/Cr and Cho/NAA
was registered and retained for the follow-up examinations. Voxel
placement was performed by the same radiologist at each
examination and was always in the same position for each patient.
This position was confirmed to be within the tumour margins that
were visible on T2-FLAIR-weighted images. The raw spectroscopic
data were processed using Spectral Analysis General Electric
software(General Electric Healthcare) for accurate quantification,
and the data were normalised against the Cr resonance signal from
the healthy contralateral symmetrical region. N-acetyl aspartate
(2.02p.p.m.), creatine (3.03p.p.m.), choline (3.22p.p.m.) and
lactate (1.36p.p.m.) resonances were assessed at the intermediate
echo time (144ms), and free lipid (0.8–1.2p.p.m.) resonances were
assessed at the short echo time (35ms). We compared the changes
over time in the Cho/Cr and Cho/NAA ratios and the resonances of
free lipids and lactates relative to changes in tumour volume.
Statistical analysis
Variables measured over the evaluation period Measurements of
variables were taken before treatment (n¼0 months) and repeated
every month during the follow-up after treatment (n¼1–14months).
Values for metabolic ratios (Cho/Cr)n and (Cho/NAA)n at n
months of follow-up (n¼0 before treatment).
Values for tumour volumes Vn (tumour size)n at n months of
follow-up (n¼0 before treatment).
Response to treatment at n months of follow-up (MRS response
patterns)n: response/no relapse vs response/relapse vs no response.
(Response)n: (response vs no response)
(Relapse)n: (relapse vs no relapse)
Variables tested over time metabolic ratios:( Cho/Cr)n and
(Cho/NAA)n, n¼number of months of follow-up (n¼0 before
treatment).
Mean metabolic ratios
Mean
Cho
Cr
  
n
¼
X k¼p
k¼1
1
k
 
Cho
Cr
  
k;n
Mean
Cho
NAA
  
n
¼
X k¼p
k¼1
1
k
 
Cho
NAA
  
k;n
n¼number of months of follow-up (n¼0 before treatment);
p¼number of patients.
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sMean relative change in metabolic ratios Mean relative change in
metabolic ratios (Cho/Cr)n and (Cho/NAA)n at n months of follow-
up compared with their corresponding reference ratio before
treatment (Cho/Cr)n and (Cho/NAA)n:
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n¼number of months of follow-up (n¼0 before treatment);
p¼number of patients.
Mean tumour volume variable
Vn ¼
X k¼p
k¼1
1
k
 Vk;n
n¼number of months of follow-up (n¼0 before treatment);
p¼number of patients.
Mean relative change in the tumour volume variable Mean
relative change in tumour volume, Vn,a tn months of follow-up
compared with baseline tumour volume before treatment, V0:
Mean
DVn
Vo
¼
X k¼p
k¼1
1
k
 
DVk;n
Vk;0
with DVk,n¼(Vk,0 Vk,n);
n¼number of months of follow-up (n¼0 before treatment);
p¼number of patients.
Mean relative difference between two different metabolic ratios Mean
relative evolution of the difference between two different metabolic
ratios, (Cho/Cr)n and (Cho/NAA)n, compared with the reference ratio
(Cho/NAA)n at n months of follow-up:
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n¼number of months of follow-up (n¼0 before treatment);
p¼number of patients.
Statistical methodology
  An initial univariate analysis was performed using Spearman’s
rank correlation coefficient to measure the statistical depen-
dence between two metabolic ratio variables or between a
metabolic ratio and a tumour volume variable. The analysis was
then carried out using linear, polynomial, exponential and
logarithmic regressions to test the temporal influence of the
monotonic relationships observed between the metabolic ratios
themselves and between the metabolic ratios and the tumour
volume variables. The Wilcoxon test was used to assess
comparisons of the differences between repeated measurements
(quantitative variables) of the metabolic ratios and the tumour
volume variables over time. To assess the significant differences
between the spectral distributions of the metabolic ratio
variables according to TMZ treatment response, the analysis
was performed using the Kruskal–Wallis test for the MRS
response patterns (qualitative variables with three classes), and
the Mann–Whitney test was used to analyse the response and
relapse variables (qualitative variables).
  A multivariate analysis was performed using the binary logistic
regression test (qualitative variable) and multiple regressions
(quantitative variable) using the LOGXACT programme (Cytel
Software, Cambridge, MA, USA) to determine independent
predictors of changes in tumour volume and predictors of
response and relapse to treatment with TMZ.
  A receiver-operating characteristic (ROC) analysis was carried
out to determine the cutoff for metabolic ratios that was
predictive of response or relapse to treatment.
  Differences were considered statistically significant when
Pp0.05. Values are expressed as mean±s.d.
RESULTS
Patient characteristics
The patient characteristics are presented in Table 1.
Tumour volume and
1H-MRS analysis
All patients showed variations in their Cho/Cr and Cho/NAA
ratios.
The results revealed three distinct
1H-MRS dynamic response
patterns. The first pattern corresponded to responders/non
relapsers: 13 patients (61.9%) responded to treatment without
relapse. The second pattern corresponded to responders/relapsers:
five patients (24%) briefly responded but then relapsed. The third
pattern corresponded to non-responders: three (14%) patients did
not demonstrated significant changes in tumour volume.
Table 1 Patient characteristics
Number of patients
Characteristics P¼21 %
Age, median (range), years 43 (32–77)
Sex
Male 7 33
Female 14 67
Histology
Oligodendroglioma 14 67
Oligoastrocytoma 5 24
Astrocytoma 2 9
Karnofsky score, median (range) 90 (80–100)
Surgery
Biopsy 12 56
Resection 9 44
Time interval from diagnosis to onset of TMZ,
median (range), months
4 (1–84)
MRI (contrast enhancement)
Yes 3 14.7
No 17 81
Abbreviations: MRI¼magnetic resonance imaging; TMZ¼temozolomide.
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sFor two of the patients (patterns 1 and 2), whose maximal values
of Cho/Cr and Cho/NAA were not observed in the same voxel, the
voxel with the maximal value of Cho/Cr was used for the follow-up
because this is the best tumour anabolism marker (Murphy et al,
2004; Lamari et al, 2008; Hlaihel et al, 2009).
Four patients showed an initial resonance of lactates: one patient
was in pattern 1, one patient was in pattern 2 and two patients
exhibited an additional resonance of free lipids (pattern 3).
Although the metabolite ratios and the volumetric parameter
were consistent, the variability in the metabolite ratios was much
greater (Figure 1);
Mean
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Cr
  
n
Cho
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o
¼ 0:272;
Mean
D Cho
NAA
  
n
Cho
NAA
  
o
¼ 0:287;
andmean
DVn
Vo
¼ 0:109
0
B B B B B B B B @
1
C C C C C C C C A
In addition, for the five patients who relapsed early after their
initial response, the minimum extremum points of the convex
metabolite ratio curves occurred at 1 month (in three cases) and
at 2 months (in the other two cases) before the minimum
extremum point of the convex volumetric curve (Figures 2 and 3).
The maximum mean relative decrease in tumour volume,
mean(DVn/Vo), was 0.183 at the 8-month follow-up, whereas the
maximum mean relative decrease in the two metabolic ratios
(mean(D(Cho/NAA)n/(Cho/NAA)o) and mean(D(Cho/Cr)n/(Cho/
Cr)o)) were 0.560 and 0.515, respectively, and both were observed
at the 6-month follow-up.
Statistical analysis
Tumour volume The mean relative variation in tumour volume
values (mean(DVn/Vo)) over time is shown in Table 2, and the
follow-up time was 14 months for each group (Figure 4).
The metabolic ratio curves Spearman’s rank correlation coeffi-
cient demonstrated, over time, a significant statistical monotonic
relationship between the two metabolic ratios (i.e., mean(Cho/Cr)n
and mean(Cho/NAA)n, in the 21-patient group, Po0.001) as well as
in the subgroups stratified according to the ‘MRS response pattern’
variable (Table 3). Mean(Cho/NAA)n decreased significantly when
mean(Cho/Cr)n decreased (Spearman r¼þ0.95) over the 14
months of follow-up, and the decrease followed a significant
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Figure 1 Evolutions over the time of the metabolic ratios and tumour volume in a patient treated with temozolomide, with a sustained response over
12 months without relapse. Note the great and rapid decrease of the metabolic ratios, compare with the low and delayed decrease of tumour volume.
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Figure 2 Evolutions over the time of the metabolic ratios and tumour volume in a patient treated with temozolomide, with a brief response and then
relapse, over the time of follow-up. Note the great and rapid changes of the metabolic ratios in both phases, compare to the low and delayed change of
tumour volume; (the minimum extremum points of the convex metabolic curves are observed at 8 month follow-up, and of the convex volumetric curve at
10 month follow-up).
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slogarithmic regression (Po0.001) that was described by the
equation Y¼1.091þ1.553 ln(X), R
2¼0.926 (Figure 5).
Both lactate and free lipid resonances, which were only relevant
for four patients, did not show any statistically significant changes.
Tumour volume and metabolic ratio curves Spearman’s rank
correlation coefficient showed over time a significant statistical
monotonic relationship between the tumour volume variable
(mean(DVn/Vo)) and the metabolic ratios (mean(Cho/Cr)n and
mean(Cho/NAA)n) in the 21-patient group (P¼0.034 and 0.008,
respectively) and in the subgroups that were stratified according
to the ‘MRS response pattern’ variable (Table 3). Mean(Cho/Cr)n
and mean(Cho/NAA)n decreased significantly when the mean
relative decrease in tumour volume (mean(DVn/Vo)) increased
(Spearman r¼ 0.750 and  0.933, respectively) over the 14
months of follow-up.
In the ‘response/no relapse’ patient group, the evolutions of
metabolic ratios, mean(Cho/Cr)n and mean(Cho/NAA)n, were
significantly correlated with the evolution of the mean relative
decrease of tumour volume, mean(DVn/Vo), over time (Po0.001),
according to a linear regression that was described by the equations
Y¼0.451–0.245 X, R
2¼0.971 and Y¼0.488–0.221 X, R
2¼0.986,
respectively (Figure 6).
In the ‘response/relapse’ patient group, the evolutions of
metabolic ratios, mean(Cho/Cr)n and mean(Cho/NAA)n, were
significantly correlated with the evolution of the mean tumour
volume (meanVn), over time (Po0.001), according to an
exponential regression described by Y¼36495.648 e
(0.577 X)
and Y¼35161.045 e
(0.602 X), respectively (Figure 7).
The metabolic ratios curves and response to treatment The mean
metabolic ratios, mean(Cho/Cr)n and mean(Cho/NAA)n, were
significantly correlated with response to treatment over time
(i.e., a 14-month follow-up) for the variable (MRS response
patterns)n (P¼0.059 and 0.031, respectively, Table 2).
In addition, the mean relative change in the metabolic ratios,
mean(D(Cho/Cr)n/(Cho/Cr)o)a n dm e a n ( D(Cho/NAA)n/(Cho/NAA)o),
were significantly correlated with response to treatment over time
Cho
Cr
NAA
43210
p.p.m. p.p.m. p.p.m. p.p.m. p.p.m.
43210 43210 43210 43210
Figure 3 A series of FLAIR images from the patient from Figure 2, together with the spectrum at long TE. The data demonstrate a reduction in tumour
volume during the response phase to temozolomide. The images displayed are (A) at 1 month, (B) 3 months, (C) 6 months, (D) 8 months after the first
dose, corresponding to the tumoural metabolism activity before tumour regrowth, and (E) at 12 months.
Table 2 Mean (±s.d.) of metabolic ratios and response to treatment
Mean
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n
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D Cho
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n
Cho
NAA
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Cho
NAA   Cho
Cr
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NAA
 !
n
No response 0.005±0.003 1.525±0.159 1.669±0.156 0.016±0.007 0.014±0.008 0.097±0.016
Response/no relapse 0.159±0.096 1.256±0.444 1.555±0.487 0.446±0.200 0.416±0.205 0.018±0.061
Response/relapse 0.116±0.057 1.253±0.465 1.266±0.450 0.255±0.220 0.323±0.204 0.004±0.070
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Figure 4 Mean relative change in tumour volume, mean(DVn/Vo), for
each pattern of response to temozolomide, over the period of follow-up.
Table 3 Spearman’s rank correlation coefficients
No
response
Response/
no relapse
Response/
relapse
Mean Cho
Cr
  
n vs mean Cho
NAA
  
n P¼0.028
r¼+0.733
Po0.001
r¼+1.000
Po0.001
r¼+0.961
Mean Cho
Cr
  
n vs meanDVn
Vo P¼0.034
r¼ 0.750
Po0.001
r¼ 1.000
P¼0.085
r¼ 0.477
Mean Cho
NAA
  
n vs meanDVn
Vo P¼0.008
r¼ 0.933
Po0.001
r¼ 1.000
P¼0.012
r¼ 0.697
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s(i.e., a 14-month follow-up) for the variable (MRS response patterns)n
(Po0.001, Table 2).
The observed trend in the metabolic ratio curves (Cho/Cr)n and
(Cho/NAA)n over time, particularly in the ‘response/relapse’
patient group, led us to develop a parameter to highlight the
variable (relapse)n. Our analysis was based on the meaning of the
evolution of tumour volume and metabolic ratios parameters over
time while taking into account (1) the more rapid decrease in the
metabolic ratio (Cho/NAA)n and the faster increase in the
metabolic ratio (Cho/Cr)n at recurrence in patients receiving
TMZ, and (2) the minimum extremum points of tumour volume
and metabolic ratios curves and the intersection point between the
metabolic curves over time. The parameter we developed was
P k¼p
k¼1
1
k  1  
Cho
Cr ðÞ k;n
Cho
NAA ðÞ k;n
  
where n is the number of months of follow-up
(n¼0 before treatment) and p is the number of patients.
It turns out that:
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which was the mean relative difference between metabolic ratios
(Cho/NAA)n and (Cho/Cr)n compared with the value of the
reference ratio (Cho/NAA)n at n months of follow-up. This
parameter was well correlated with the variable (relapse)n at n
months of follow-up (Po0.001), and not with the variable
(response)n (P¼0.541, Table 2).
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Figure 5 The evolutions of the metabolic ratios, mean(Cho/Cr)n and
mean(Cho/NAA)n, were significantly correlated over time (Spearman
r¼þ0.95) and followed a logarithmic regression
(Y¼1091þ1553 ln(X); R
2¼0.926, Po0.001).
Y = 36495.648 × e(0.577 × X) Y = 35161.045 × e(0.602 × X)
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Figure 7 In the ‘response/relapse’ patient group, the evolutions over time of metabolic ratios, mean(Cho/Cr)n and mean(Cho/NAA)n, were significantly
correlated with the evolution of the mean tumour volume (meanVn), according to an exponential regression (Y¼36495.648 e
(0.577 X), Po0.001 and
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The mean relative decrease of metabolic ratio, mean(D(Cho/Cr)n/
(Cho/Cr)o), at n¼3 months after starting treatment with TMZ, was
an independent predictive factor of tumour response, (response)n,
over the 14 months of follow-up (P¼0.0364; mean(D(Cho/Cr)n/
(Cho/Cr)o)¼0.234±0.141). No significant cutoff for the mean
(D(Cho/Cr)n/(Cho/Cr)o) was found for predicting the tumour
response from the ROC analysis (Table 4).
With respect to the variable (relapse)n: The mean relative change
between metabolic ratios, mean
Cho
NAA ðÞ n  Cho
Cr ðÞ n
Cho
NAA ðÞ n
,a tn¼4 months after
starting treatment with TMZ, was an independent predictive factor
of tumour relapse, (relapse)n, over the 14 months of follow-up
(P¼0.058; mean
Cho
NAA ðÞ n  Cho
Cr ðÞ n
Cho
NAA ðÞ n
¼0.134±0.110). A significant cutoff
of 0.046 for mean
Cho
NAA ðÞ n  Cho
Cr ðÞ n
Cho
NAA ðÞ n
with a sensitivity of 60% and a
specificity of 100% (P¼0.004) was found for predicting tumour
relapse from the ROC analysis (Table 5).
This study was approved by the local ethics committee.
DISCUSSION
In general, our results are internally consistent. The metabolic
ratio and volumetric curves were similar in evolution for both the
response and relapse phases.
In each instance, our pretreatment spectroscopic data demon-
strated higher choline and creatine levels and lower NAA levels
relative to normal parenchyma. Moreover, five patients had
additional resonances of lactates and/or free lipids, which agreed
with the general metabolic profile of glial tumours reported by
several groups (Negendank et al, 1996; Nelson et al, 1999).
Immediately following the first month of treatment, however, we
observed a clear, dramatic change in the metabolite ratios com-
pared with tumour volume. The Cho/Cr and Cho/NAA ratios both
decreased dramatically to the same extent, whereas tumour volume
decreased much more slowly. This decrease in metabolic ratios was
most likely a direct consequence of the therapeutic effect of TMZ
and subsequent neoplastic cell death (Miller et al, 1996).
The second major finding of this study was a minimum
extremum point in the metabolite curve, which appeared at
2 months in average before the same event registered on the
tumour volume curve. This phenomenon was observed in all five
patients with tumour recurrence, which suggests that
1H-MRS may
be an earlier marker of tumour recurrence than volumetric data.
In addition, this observation was consistent with the study of
Tedeschi et al (1997). Moreover, a minimal change in tumour
volume (registered using volumetric software in this study) may be
difficult to assess with other methods, such as MTD, which could
cause a delay in its assessment. Thus,
1H-MRS may provide
additional time to optimise adjuvant therapy. After the intersection
point between the metabolic curves, we observed a dramatic
increase in both the Cho/NAA and Cho/Cr ratios. In addition, the
range of variation of metabolite changes was much more wider than
the variation in tumour volume in this part of the curve and in the
response phase.
This difference between the metabolite ratios and the volume
curves was not observed by either Murphy et al (2004) or Hlaihel
et al (2009) who both reported that the metabolite ratios and
tumour volume changed in parallel over time. In our opinion, this
discrepancy emphasises the importance of being able to repro-
ducibly position the voxel in the same precise location from one
examination to another in the same patient, which we sought to
achieve in this study. Indeed, our spectroscopic data were acquired
using the same protocol at each examination for each patient. To
the best of our knowledge, this study is the first multivariate
analysis of spectroscopic data to provide predictive factors of LGG
response during TMZ treatment. Indeed, the mean relative
decrease in the Cho/Cr ratio slope at 3 months after initiation of
TMZ chemotherapy was predictive of the response of the tumour
over 14 months of follow-up. This last point emphasises the
importance of using the Cho/Cr ratio slope as a tumour anabolism
marker without regard to the degree of neuroaxonal tissue
impairment. Cho/NAA was not a predictive factor for response,
however, which was consistent with a previous study performed by
(Hlaihel et al, 2009). In addition, the mean relative decrease
between the Cho/Cr and Cho/NAA ratio slopes after 4 months of
treatment was predictive of relapse over 14 months of follow-up,
and their relative evolution immediately after treatment onset may
be predictive of relapse over the follow-up period. Moreover, 0.046
was the significant cutoff of the predictive factor for the relapse
variable, which has 100% specificity and 60% sensitivity. This
value provides a reliable index of relapse risk that may be useful in
clinical decision making. Conversely, no significant cutoff of
Cho/Cr was found for the response variable. Although 14 months
of follow-up may be considered too short by some authors
(Murphy et al, 2004), it was a sufficient amount of time for early
predictive factors of outcome to arise in this study.
The difference observed in this study between earlier and wider
variations of the metabolite ratio parameters (Cho/Cr and
Cho/NAA) and volumetric variations, both during the same short
period, underlines the importance and complementary nature of
these two measurements for monitoring the LGG response to TMZ.
This difference holds true for both the response and relapse
phases, and was consistent with the idea that metabolic changes
both precede and determine morphological changes and tumour
growth (Julia-Sape et al, 2006). The observation of both lactate and
free lipid resonances may provide additional information regard-
ing LGG metabolic behaviour, which we noted in a previous report
(Lamari et al, 2008). The limited number of concerned patients
(two) in this study, however, precluded our ability to draw any
meaningful conclusions.
Methodologically, the heterogeneity of the metabolic behaviour
of the tumour cannot be fully assessed by a single voxel
measurement. As stated in the Materials and methods section,
however, we sampled the entire lesion in our initial exploration,
retained the most pejorative spectra, and then performed a study-
to-study registration for voxel placement to minimise measure-
ment errors that could lead to variability of biological factors.
Few authors have reported variability in the response to TMZ
treatment (Chinot, 2001; Byrne, 2004). Some patients respond early
(i.e., in the first month), whereas others react long after the first
dose (i.e., after several months), which was the case in three of our
patients in the ‘non-responder’ group. Likewise, timing of the
relapse phase can also be variable. Hence, it is important to
monitor patients over a long period (e.g., the entire TMZ treatment
Table 4 Receiver-operating characteristic analysis of Cho/Cr with respect
to the variable ‘response’
Cho/Cr Cutoff Sensibility (%) Specificity (%) Area P
Response 1.592 66.67 66.67 0.575 0.693
Table 5 Receiver-operating characteristic analysis of
(1 (Cho/Cr/Cho/NAA)n) with respect to the variable ‘relapse’
Cho
NAA   Cho
Cr
Cho
NAA
 !
n
Cutoff Sensibility (%) Specificity (%) Area P
Relapse 0.046 60 100 0.808 0.004
Predicting glioma outcome by MRS
R Guillevin et al
1860
British Journal of Cancer (2011) 104(12), 1854–1861 & 2011 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
scourse) even though predictive factors may have been determined
early in the follow-up, which was the case in this study.
CONCLUSIONS
This study demonstrated concordance between
1H-MRS and
tumour volume, which suggests that spectroscopy performed
during MRI examination is valuable in the longitudinal follow-up
of LGG that are being treated with TMZ. Our results indicate that
the
1H-MRS profile of LGG (i) changes more widely and rapidly
than tumour volume during both the response and relapse phases,
(ii) is indicative of metabolite turnover before resumption in
tumour growth and (iii) serves as an early predictive factor of
outcome over a 14-month follow-up. Hence,
1H-MRS is a
promising, noninvasive tool for predicting and monitoring the
clinical response to TMZ.
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